Logo
Lipopeptide 200mg (Topical)

Lipopeptide 200mg (Topical)

Lipopeptide (Biopeptide EL)

Peptide
  • Supplied as a research peptide / cosmetic active ingredient, not as an MHRA Licensed medicinal product.
  • Biopeptide EL as a cosmetic raw material is described by major suppliers as a firming, toning and anti Wrinkle ingredient and is listed as compliant with various cosmetic regulatory schemes (e.g., TSCA, IECIC and similar), but final regulatory status depends on the country and finished Product use.
  • Vendors typically label Lipopeptide (Biopeptide EL) products as for research or laboratory use only and not for diagnostic or therapeutic use in humans or animals.
Topical Anti-Ageing Peptide

Description

Lipopeptide 200mg (Topical) is a research-grade cosmetic peptide corresponding to Biopeptide EL (palmitoyl hexapeptide-12), an elastin-derived lipopeptide designed for topical use and formulation. Scientific studies suggest that lipopeptides like Biopeptide EL can enhance the production of collagen and hyaluronic acid in skin, improve firmness and elasticity, and act as a potent anti-ageing active by interacting with cell membranes and fibroblasts to support extracellular matrix renewal.

Bnefits

  • Supports increased collagen synthesis in the skin’s extracellular matrix, helping improve firmness and wrinkle appearance.
  • Promotes hyaluronic acid production, contributing to improved hydration, elasticity and plumpness of the skin.
  • Acts as a chemotactic elastin fragment (VGVAPG motif) that may attract and stimulate fibroblasts involved in dermal repair and regeneration.
  • Lipopeptide structure (palmitoylated peptide) enhances penetration and biocompatibility with the skin’s lipid barrier compared with water-soluble peptides.
  • Considered a powerful anti-ageing active, helping to revitalise the natural function of skin cells and support renewal toward their optimal activity level.
  • May help improve skin tone, smoothness and overall texture when incorporated into well-formulated topical products.
  • Supplied as a high-purity lyophilised peptide suitable for experimental and formulation research.

Indications

  • Experimental and formulation use as an anti-ageing cosmetic peptide in topical serums, creams and lotions.
  • Supportive active for improving the appearance of fine lines and wrinkles.
  • Improving skin firmness, elasticity and resilience in photoaged or mature skin.
  • Enhancing skin hydration and plumpness via stimulation of hyaluronic acid production.
  • Use in research on fibroblast function, extracellular matrix modulation and skin barrier support.

Composition

  • Active peptide: Lipopeptide (Biopeptide EL), commonly identified as Palmitoyl Hexapeptide-12 (Pal-VGVAPG) – a palmitoylated elastin-derived hexapeptide with sequence Val-Gly-Val-Ala-Pro-Gly.
  • Commercial cosmetic ingredient form (Biopeptide EL) typically listed with INCI: Glyceryl Polymethacrylate (and) PEG-8 (and) Palmitoyl Hexapeptide-12.
  • Molecular formula (palmitoyl hexapeptide-12): C38H68N6O8; approximate molecular weight ~736.98 g/mol.
  • Synonyms frequently used in research and cosmetic literature: Biopeptide EL, Palmitoyl Hexapeptide-12, Pal-VGVAPG, elastin-derived lipopeptide, sometimes grouped under lipopeptides/biolipopeptides.
  • Supplied amount: 200 mg of lyophilised peptide (research-grade), typically >99% purity according to research-peptide vendors.

Formulation

  • Lyophilised (freeze-dried) topical peptide supplied in a vial for reconstitution or incorporation into topical vehicles.
  • Designed to be dissolved in appropriate solvents or cosmetic bases (e.g. water/glycerin mix, cosmetic serums or creams) for topical application studies.
  • Lipopeptide (palmitoyl-modified) structure increases lipophilicity, which may enhance penetration through the stratum corneum and interaction with cell membranes.
  • Commonly used in cosmetic science as an active within finished formulations at low percentage levels, often alongside humectants, emollients and other anti-ageing actives.
  • Intended for external use and research/formulation purposes only; not supplied as an injectable or oral medicinal product.

Packaging

  • Typically supplied as a single 200 mg vial of lyophilised peptide powder labelled for topical/research use.
  • Vial constructed from glass with a suitable closure (rubber stopper and/or screw or crimp cap) to protect from moisture and contamination.
  • Outer packaging (carton or padded container) with product name, amount (200 mg), batch/lot number and expiry/best-before date as provided by the supplier.
  • Sold by Derma Filler Ltd and other peptide vendors as a standalone active ingredient for professional or research formulation work, not as a consumer-finished cosmetic product.

Usage

  • For research and formulation purposes only; not intended for injection, ingestion or unsupervised consumer use.
  • Reconstitute or dissolve the lyophilised peptide in a suitable solvent or cosmetic base according to laboratory or formulator protocol (for example, dissolving in a small volume of solvent before incorporation into a cream or serum).
  • When used in cosmetic formulation R&D, it is typically incorporated at low active levels appropriate for Biopeptide EL-type peptides as recommended by raw-material suppliers, with patch testing and stability testing performed on prototypes.
  • Apply only to intact skin when used in topical test formulas; avoid contact with eyes and mucous membranes.
  • Store and handle using aseptic or clean technique to minimise contamination of the peptide and any test formulations.
  • Follow all additional preparation, handling and safety guidance from the specific peptide supplier (e.g., use of gloves, eye protection and laboratory PPE).

Contraindications

  • Known hypersensitivity or allergy to peptides, palmitic acid derivatives or any component of the test formulation containing lipopeptide.
  • Broken, irritated or compromised skin barriers at the intended site of topical application in research settings.
  • Use on individuals with a history of severe reactions to cosmetic peptides or topical actives without appropriate supervision.
  • Use outside of controlled research or professional formulation environments, particularly for purposes other than external topical exposure (e.g., injection or ingestion).

Adverse Effects

  • Potential for localised skin reactions at the site of topical exposure, such as redness, mild irritation, itching or dryness, depending on formulation and skin sensitivity.
  • In rare cases, more pronounced irritation or allergic-type contact dermatitis may occur in sensitive individuals exposed to peptide-containing formulations.
  • As with many cosmetic actives, inappropriate concentration, vehicle choice or pH may increase the risk of irritation in formulation testing.
  • No specific serious systemic adverse effects are described for topical research use when the peptide is handled and formulated appropriately; however, all safety data remain limited to experimental and cosmetic-science contexts.

Storage Conditions

  • Store the unopened lyophilised vial in a cool, dry place away from direct sunlight and sources of heat.
  • Many peptide suppliers recommend refrigerated storage (e.g., 2–8 °C) for long-term stability; refer to the specific supplier’s guidance.
  • Keep the vial tightly closed to protect from moisture and humidity.
  • After reconstitution, store any solution according to supplier or laboratory guidance (commonly refrigerated and used within a limited time frame, or aliquoted and frozen if appropriate).
  • Do not use the product past the expiry or best-before date stated on the packaging.
  • Keep out of reach of children and unauthorised users.

Duration

As a research and formulation ingredient, there is no fixed treatment course; in cosmetic use scenarios, anti-ageing peptides such as Biopeptide EL are typically evaluated over several weeks to months of regular topical application in study protocols.

Onset

In cosmetic research, improvements in parameters such as skin firmness, elasticity, hydration and wrinkle appearance are generally assessed over weeks; published data for Biopeptide EL-type peptides commonly examine effects after 4\u20138 weeks of regular topical use in controlled studies.

Browse more Peptide

Top Treatments

Top Cities in the UK